Core Viewpoint - Cardiol Therapeutics Inc. is advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease and will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 [1][2]. Company Overview - Cardiol Therapeutics Inc. is a late-stage life sciences company focused on therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting inflammation and fibrosis related to conditions such as pericarditis, myocarditis, and heart failure [3]. Clinical Programs - The MAVERIC Program is evaluating CardiolRx™ for recurrent pericarditis, with a completed Phase II study and an ongoing pivotal Phase III trial. The U.S. FDA has granted Orphan Drug Designation for CardiolRx™ in this context [4]. - The ARCHER Program is studying CardiolRx™ in acute myocarditis, a significant cause of heart failure and sudden cardiac death in young adults, with a completed Phase II study assessing safety and efficacy [5]. Additional Developments - The company is also developing CRD-38, a novel subcutaneously administered drug formulation for inflammatory heart disease, including heart failure, which incurs healthcare costs exceeding US$30 billion annually in the U.S. [6].

Core Insights - Cardiol Therapeutics Inc. has published results from its Phase II ARCHER study, demonstrating the efficacy of its lead drug candidate, CardiolRx™, in treating acute myocarditis, which is a significant cause of heart failure in young adults [1][2][3] Company Overview - Cardiol Therapeutics Inc. is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRx™ [6][9] - The company is also developing CRD-38, a novel subcutaneously administered drug formulation aimed at treating inflammatory heart disease, including heart failure, which incurs healthcare costs exceeding US$30 billion annually in the U.S. [9] Study Findings - The Phase II ARCHER study involved 109 patients and showed that treatment with CardiolRx™ resulted in a significant reduction in left ventricular mass by 9.2 grams compared to placebo (p=0.0117), alongside decreased left atrial remodeling and favorable trends in myocardial inflammation markers [3][4] - The safety and tolerability of CardiolRx™ were confirmed in the study, indicating its potential to improve clinical outcomes in myocarditis patients [3] Ongoing Trials - The biological signals observed in the ARCHER study are relevant to Cardiol's ongoing pivotal Phase III MAVERIC trial, which focuses on recurrent pericarditis, an inflammatory disease of the pericardium [4][7] - The MAVERIC program includes the completed Phase II MAvERIC-Pilot study and the ongoing Phase III MAVERIC trial, with the U.S. FDA granting Orphan Drug Designation to CardiolRx™ for recurrent pericarditis [7] Management Commentary - The CEO of Cardiol Therapeutics emphasized that the publication of the ARCHER study results enhances confidence in the MAVERIC trial and highlights CardiolRx's impact on inflammatory heart disease [5]

Core Viewpoint - Cardiol Therapeutics Inc. has successfully completed a private placement of units, raising a total of $14.85 million to support its research and clinical development programs for heart disease therapies [1][3]. Financing Details - The company issued 11,423,078 units at a price of $1.30 per unit, which includes the full exercise of the over-allotment option by the underwriter [1]. - Each unit consists of one Class A common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2]. - The underwriter received a cash commission of 6% of the aggregate gross proceeds from the offering [2]. Use of Proceeds - The net proceeds from the financing will be utilized to advance research and clinical development programs, as well as for general administrative expenses and working capital [3]. Regulatory Compliance - The offering was conducted as a private placement under National Instrument 45-106, allowing sales to qualified investors in Canada, excluding Quebec [4]. - The units issued are not subject to resale restrictions in Canada under applicable securities laws [4]. Company Overview - Cardiol Therapeutics is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting inflammation and fibrosis associated with heart conditions [6]. - The company is conducting the MAVERIC Program to evaluate CardiolRx™ for recurrent pericarditis and has received Orphan Drug Designation from the U.S. FDA for this treatment [7]. - Additionally, the ARCHER Program is studying CardiolRx™ for acute myocarditis, a significant cause of heart failure in young adults [8]. - Cardiol is also developing CRD-38, a novel subcutaneous drug formulation for inflammatory heart disease, addressing a major healthcare cost issue in the U.S. [9].

Core Viewpoint - Cardiol Therapeutics Inc. has announced a private placement offering to raise gross proceeds of $13.5 million by selling 10,384,616 units at a price of $1.30 per unit, with an option for the underwriter to purchase an additional 10% of the units sold [1][4]. Group 1: Offering Details - The offering consists of units that include one Class A common share and one-half of a common share purchase warrant, with each warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2]. - The offering is scheduled to close on or about January 23, 2026, subject to necessary approvals, including TSX approval, and the negotiation of an underwriting agreement [4]. - A cash commission of 6% of the aggregate gross proceeds will be paid to the underwriter upon closing of the offering [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance the company's research and clinical development programs, as well as for general and administrative expenses and working capital [3]. Group 3: Company Overview - Cardiol Therapeutics is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting conditions like pericarditis and myocarditis [9][10]. - The company is also developing CRD-38, a novel drug formulation for treating inflammatory heart disease, which is a significant cause of death and hospitalization in developed countries [12].

Core Viewpoint - Cardiol Therapeutics Inc. has announced a private placement offering to raise gross proceeds of $13.5 million by selling 10,384,616 units at a price of $1.30 per unit, with an option for the underwriter to purchase an additional 10% of the units sold [1][4] Group 1: Offering Details - The offering consists of units that include one Class A common share and one-half of a common share purchase warrant, with each warrant allowing the purchase of one common share at an exercise price of $1.75 for 24 months [2] - The offering is scheduled to close on or about January 23, 2026, subject to necessary approvals, including from the TSX [4] - A cash commission of 6% of the aggregate gross proceeds will be paid to the underwriter upon closing [4] Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance research and clinical development programs, as well as for general administrative expenses and working capital [3] Group 3: Company Overview - Cardiol Therapeutics is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate, CardiolRx™, targeting conditions like pericarditis and myocarditis [9][10] - The company is also developing CRD-38, a novel drug formulation for inflammatory heart disease, which is a significant cause of death and hospitalization in developed countries [12]

Core Insights - Cardiol Therapeutics Inc. has surpassed 50% patient enrollment in its Phase III MAVERIC trial, which evaluates CardiolRx™ for preventing disease recurrence in patients with recurrent pericarditis [1][2][3] Company Overview - Cardiol Therapeutics is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRx™ [5][9] - The company aims to address the high unmet medical need in recurrent pericarditis, a condition that significantly impacts patients' quality of life [7] Clinical Trial Progress - The MAVERIC trial is designed to enroll approximately 110 patients across 25 leading cardiovascular research centers in the U.S., Canada, and Europe, with full enrollment expected by Q2 2026 [4][6] - The primary endpoint of the trial is freedom from new episodes of recurrent pericarditis after six months of treatment, with secondary endpoints including pain scores and inflammatory biomarker changes [4] Scientific Rationale and Market Potential - Data from the Phase II MAvERIC-Pilot study showed that CardiolRx™ led to rapid and sustained reductions in pericarditis pain and inflammation, supporting its advancement to Phase III [3][4] - The company believes that CardiolRx™'s oral, non-immunosuppressive profile positions it as a more accessible treatment option compared to biologic therapies, which are projected to generate over $800 million in U.S. revenues in 2026 [3][4]

Core Insights - Cardiol Therapeutics Inc. announced significant findings from the Phase II ARCHER trial, demonstrating that CardiolRx™ improves heart structure in patients with acute myocarditis, supporting its potential for broader applications in inflammatory cardiac conditions [2][4][5] Group 1: Trial Results - The ARCHER trial showed a significant reduction in left ventricular (LV) mass by 9.2 grams (from 130.3g in placebo to 121.1g in the active group, p=0.0117), indicating meaningful structural recovery [3][8] - Extracellular volume (ECV) decreased by 3.7 mL (from 37.3mL in placebo to 33.6mL in the active group, p=0.0538), and intracellular volume (ICV) reduced by 5.6 mL (from 91.2mL in placebo to 85.6mL in the active group, p=0.0928) [8][9] - Left atrial end systolic volume (LAESV) was reduced by 8.1 mL (p=0.0376) and left ventricular end diastolic volume (LVEDV) decreased by 7.4 mL (p=0.0981), reflecting improved heart function [8][9] Group 2: Clinical Implications - The results provide clinical evidence that CardiolRx™ can reduce inflammation-driven structural damage in the heart, a key factor in heart failure progression [4][5] - The findings support the scientific rationale for Cardiol's lead Phase III program in recurrent pericarditis and indicate potential for development across various inflammatory cardiac conditions [4][5][17] Group 3: Company Overview - Cardiol Therapeutics is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with CardiolRx™ as its lead candidate [15][18] - The company is also advancing CRD-38, a next-generation small molecule targeting chronic inflammatory heart conditions [18]

Core Insights - Cardiol Therapeutics has received a Notice of Allowance for a U.S. patent that will protect its heart drugs until late 2040, specifically for CardiolRx™ and CRD-38 in treating various cardiac conditions [2][3][5] Intellectual Property Protection - The new patent will provide broad intellectual property protection for Cardiol's therapies against a range of heart diseases, including heart failure, myocarditis, and atherosclerosis [2][5] - This patent allowance enhances Cardiol's market position and intellectual property portfolio, complementing its existing U.S. Orphan Drug Designation for pericarditis [3][5] Clinical Development Programs - Cardiol is advancing late-stage clinical programs for recurrent pericarditis and acute myocarditis, addressing significant unmet medical needs [3][9] - The company is preparing to initiate first-in-human clinical evaluations of CRD-38, a novel therapy for inflammatory heart disease, including heart failure [3][9] Upcoming Presentations and Trials - Cardiol plans to present comprehensive data from the ARCHER trial, a Phase II study of CardiolRx™ in acute myocarditis, at the European Society of Cardiology Annual Meeting on November 29 [3][8] - An update on the pivotal Phase III MAVERIC trial in recurrent pericarditis will also be provided as patient enrollment accelerates [3][7]

Core Insights - Cardiol Therapeutics is set to present full data from its Phase II ARCHER trial at the European Society of Cardiology meeting, focusing on the effects of CardiolRx™ in patients with acute myocarditis [2][5] - The trial demonstrated significant improvements in cardiac structure, including a notable reduction in left ventricular mass, indicating the potential of CardiolRx™ as an effective anti-inflammatory treatment for heart disease [3][4][6] Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company specializing in late-stage anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRx™ [8] - The company is also developing CRD-38, a novel subcutaneously administered formulation aimed at treating heart failure, which is a leading cause of death and hospitalization globally [11] Trial Details - The ARCHER trial enrolled 109 patients from various countries, including the United States, France, Brazil, and Israel, to assess the safety and efficacy of CardiolRx™ in acute myocarditis [6] - The trial's design and rationale were previously published, emphasizing the importance of addressing inflammation in cardiac conditions [6] Upcoming Events - A webcast conference call is scheduled for December 1, 2025, to discuss the ARCHER trial findings and their implications for Cardiol's future programs in inflammatory heart disease [7]

Core Insights - Cardiol Therapeutics Inc. has successfully completed a private placement offering, raising US$11.4 million to support its operations and development of heart disease therapies [3][4]. Financing Details - The company sold a total of 11.4 million units at a price of US$1.00 per unit, with each unit consisting of one common share and one-half of a common share purchase warrant [4]. - The warrants allow holders to acquire additional common shares at an exercise price of US$1.35 for 24 months, with an acceleration provision if the share price exceeds US$2.00 for five consecutive trading days [4]. Clinical Development - The funds will support the ongoing pivotal Phase III MAVERIC trial for CardiolRx™, which targets recurrent pericarditis, and the development of the next-generation CRD-38 formulation for heart failure [6][10]. - Recent findings from the ARCHER trial indicate a significant reduction in left ventricular (LV) mass, providing clinical validation for Cardiol's therapies in inflammatory heart disease [4][12]. Market Potential - The company aims to address a significant unmet need in heart failure, where five-year mortality rates exceed 50%, and healthcare costs in the U.S. related to heart failure exceed US$30 billion annually [4][12].